| __timestamp | Genmab A/S | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 5496000 |
| Thursday, January 1, 2015 | 91224000 | 9786000 |
| Friday, January 1, 2016 | 102413000 | 6792000 |
| Sunday, January 1, 2017 | 146987000 | 7313000 |
| Monday, January 1, 2018 | 213695000 | 8382000 |
| Tuesday, January 1, 2019 | 342000000 | 10803000 |
| Wednesday, January 1, 2020 | 661000000 | 12944000 |
| Friday, January 1, 2021 | 1283000000 | 21967000 |
| Saturday, January 1, 2022 | 2676000000 | 32810000 |
| Sunday, January 1, 2023 | 3297000000 | 46542000 |
| Monday, January 1, 2024 | 3790000000 |
Data in motion
In the dynamic world of pharmaceuticals, understanding financial trends is crucial. Over the past decade, Genmab A/S and Xenon Pharmaceuticals Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Genmab A/S, a leader in antibody therapeutics, has seen its SG&A expenses skyrocket by over 4,000% from 2014 to 2023, reflecting its aggressive expansion and market penetration strategies. In contrast, Xenon Pharmaceuticals Inc., specializing in neurology, has experienced a more modest increase of approximately 750% during the same period. This divergence highlights Genmab's rapid growth and strategic investments compared to Xenon's steady, focused approach. As the pharmaceutical landscape evolves, these trends offer valuable insights into each company's operational priorities and market strategies.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.